Gregory Garland - Amgen Insider

AMGN -- USA Stock  

USD 185.01  1.06  0.58%

Independent Director

Mr. Gregory C. Garland is an Independent Director of Amgen Inc. Mr. Greg C. Garland is the Chairman and Chief Executive Officer of Phillips 66, an energy manufacturing and logistics company with midstream, chemical, refining and marketing and specialties businesses created through the repositioning of ConocoPhillips, having held this position since April 2012. Mr. Garland chairs the Executive Committee of Phillips 66. Prior to Phillips 66, Mr. Garland served as Senior Vice President, Exploration and Production, Americas of ConocoPhillips from 2010 to April 2012. He was President and Chief Executive Officer of Chevron Phillips Chemical Company from 2008 to 2010 and Senior Vice President, Planning and Specialty Chemicals from 2000 to 2008. Mr. Garland served in various positions at Phillips Petroleum Company from 1980 to 2000. Mr. Garland is a member of the Engineering Advisory Board for Texas AM University. Mr. Garland received an undergraduate degree from Texas AM University.
Age: 58  Director Since 2013      
805-447-1000  http://www.amgen.com

Management Efficiency

The company has return on total asset (ROA) of 8.84 % which means that it generated profit of $8.84 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 9.59 % meaning that it created $9.59 on every $100 dollars invested by stockholders.
The company currently holds 35.54 B in liabilities with Debt to Equity (D/E) ratio of 227.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Amgen has Current Ratio of 3.8 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

James FarrellAbbott Laboratories
2006
Fred WeissAllergan plc
2013
Marschall RungeEli Lilly and Company
2013
Nancy McKinstryAbbott Laboratories
2011
Roxanne AustinAbbott Laboratories
2000
Todd SisitskyEndo International plc
2016
Jill SmithEndo International plc
N/A
David GreenwayVertex Pharmaceuticals Incorpor
2017
Anne WhitakerMallinckrodt Public Limited Com
2018
Kathi SeifertEli Lilly and Company
1995
Michael GrobsteinBristol Myers Squibb Company
2007
Thomas LynchBristol Myers Squibb Company
2017
William KaelinEli Lilly and Company
2012
Franklyn PrendergastEli Lilly and Company
1995
Sharad MansukaniEndo International plc
2017
Diane GulyasMallinckrodt Public Limited Com
2013
Jamere JacksonEli Lilly and Company
2016
Gregory HinckleyBio Rad Laboratories
2017
Michelle KumbierAbbott Laboratories
2018
Adriane BrownAllergan plc
2017
Thomas CechMerck Co
2009

Entity Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. Amgen operates under Biotechnology classification in USA and traded on NASDAQ. It employs 20800 people.Amgen (AMGN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 20,800 people. Amgen is listed under Pharmaceutical Products category by Fama And French industry classification.

Amgen Leadership Team

Frank Herringer, Director
Francois Carbonnel, Director
Rebecca Henderson, Director, Ph.D
Annette Such, Executive
Sanders Williams, Director
Vance Coffman, Director, Ph.D
Tyler Jacks, Director, Ph.D
Brian McNamee, President
Gregory Garland, Director
Charles Holley, Director
Esteban Santos, President
Jonathan Graham, President
Sean Harper, President, Ph.D
Ellen Kullman, Director
Frank Biondi, Director
Arvind Sood, Executive
David Meline, CFO
Ronald Sugar, Director
Stuart Tross, President
Robert Bradway, Chairman
Wanda Austin, Director
Robert Eckert, Director
Madhavan Balachandran, EVP
Lori Johnston, President
Cynthia Patton, President
Greg Garland, Director
Judith Pelham, Director
David Baltimore, Director, Ph.D
Fred Hassan, Director
David Piacquad, President
Anthony Hooper, EVP

Stock Performance Indicators

Did you try this?

Run Cryptocurrency Arbitrage Now
   

Cryptocurrency Arbitrage

Find pairs of digital assets on multiple exchanges that are traded at a risk free arbitrage
All  Next Launch Cryptocurrency Arbitrage

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Amgen and IQVIA Holdings. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try ETF Directory module to find actively-traded exchange traded funds (etf) from around the world.